OncoFirm™ / Research / Human cancer antigens
Research explainer · Glycobiology
What Causes High Thomsen–Friedenreich (TF) Antigen? Cancer, Infection, Inflammation and Beyond
The Thomsen–Friedenreich (TF) antigen is a small sugar that healthy cells usually keep hidden. When it is exposed, or measured at high levels, the usual suspect is cancer, but it is not the only one. Bacterial enzymes, inflammation, normal development and even laboratory handling can all reveal TF. This guide explains how cells normally hide TF, the four main routes by which it becomes exposed, and what a high result can and cannot tell you.
At a glance
What TF is
Galβ1-3GalNAc on proteins; also called T antigen or CD176
Normal state
Hidden by sialic acid or extended into longer sugar chains
Main causes of exposure
Cancer glycosylation, microbial neuraminidase, inflammation, development
Key caution
Not specific to cancer; no validated clinical blood test or reference range
OncoFirm™ status
TF research in development; not FDA cleared or approved
On this page
Key points
High TF antigen in brief
~90%of carcinomas showed T or Tn antigen exposure in Springer's landmark 1984 review
4 routesto exposed TF: cancer glycosylation, microbial neuraminidase, inflammation and development
0FDA-cleared blood tests for TF antigen in cancer detection today
Figures are from the peer-reviewed sources listed in the references.
Definition
What is the Thomsen–Friedenreich antigen?
The Thomsen–Friedenreich (TF) antigen, also called the T antigen or CD176, is the disaccharide galactose-β1,3-N-acetylgalactosamine (Galβ1-3GalNAc) attached to serine or threonine on proteins. It is the core 1 structure of mucin-type O-glycans and is an oncofetal antigen: present in fetal tissue, largely hidden in healthy adult cells, and exposed again in many cancers.
TF is commonly carried by mucins such as MUC1. It is usually detected with lectins such as peanut agglutinin (PNA), a sugar-binding protein rather than an antibody, or with anti-TF monoclonal antibodies. For the basics, see our TF antigen overview.
Cause 1 · Cancer
Glycosylation changes in cancer cells
Cancer is the best-known cause of exposed TF. In his 1984 review in Science, Georg Springer reported T or Tn exposure in about 90% of carcinomas. TF has since been described in breast, colorectal, gastric, pancreatic, lung, bladder, prostate and ovarian carcinomas, and in some leukemias.
- Stalled elongation. Reduced C2GnT1 activity, seen in many breast and other carcinomas, leaves core 1 structures unextended.
- Shifts in sialylation. Changes in sialyltransferases alter the balance between TF and sialyl-TF. In breast cancer, raised ST3Gal1 often makes sialyl-TF dominant, so exposed TF and sialyl-TF should be considered together.
- Golgi disorganization. Altered Golgi structure, pH and enzyme localization in cancer cells disturb the orderly assembly of O-glycans.
- More carrier protein. Overexpressed, under-glycosylated mucins such as MUC1 present more truncated glycans on the cell surface and in shed fragments.
- Cosmc loss leads to Tn. Mutation or silencing of Cosmc blocks T-synthase and exposes Tn and sialyl-Tn instead of TF, a related but distinct route.
TF exposure is not only a marker. In colorectal cancer it has been linked with a worse prognosis, and on MUC1 it can bind circulating galectin-3 and increase cancer-cell adhesion to blood vessels in laboratory studies. See tumor antigen detection.
Cause 2 · Infection
Microbial neuraminidase and T-activation
Some bacteria and viruses make neuraminidase (sialidase), an enzyme that removes sialic acid. When it acts on red cells, platelets or endothelium it exposes TF, a process called T-activation. Well-described causes include Streptococcus pneumoniae and Clostridium perfringens.
- Hemolysis. Most people over about six months of age carry natural anti-T IgM antibodies, which can bind T-activated cells. T-activation is associated with pneumococcal hemolytic uremic syndrome and with necrotizing enterocolitis in infants.
- Blood-bank recognition. Transfusion laboratories identify T-activated red cells with lectins such as peanut agglutinin, and may use washed red cells or low anti-T products for affected patients.
- Sepsis. In pneumococcal sepsis, desialylated platelets are cleared by the liver's Ashwell–Morell receptor, contributing to low platelet counts.
These are acute, infection-driven changes. They show that a raised TF signal in blood can come from causes entirely unrelated to cancer.
Cause 3 · Inflammation
Inflammation and precancerous change
In 1995, researchers at the University of Liverpool showed directly that TF is increased in mucin from colonic adenocarcinoma and from ulcerative colitis, while it is concealed in normal colonic mucin. Chronic inflammation alters mucin glycosylation, and similar changes are seen in some precancerous lesions such as colonic adenomas.
This matters for diagnostics: inflammatory and benign conditions are among the most likely sources of false-positive TF results, so they must be included when any TF test is validated.
Cause 4 · Development and other states
Development, normal tissue and rare conditions
- Fetal development. TF is an oncofetal antigen, expressed in fetal tissues and largely masked after birth.
- Some normal cells. Small amounts of TF are present in certain normal tissues and cell compartments, so a low background signal is expected.
- Rare red-cell conditions. Inherited or acquired polyagglutination states, including Tn syndrome caused by somatic Cosmc mutation in blood-forming cells, change red-cell glycans. Tn syndrome exposes Tn rather than TF, which is why the two must be distinguished.
Cause 5 · Measurement
Laboratory factors that can mimic high TF
- Reagent specificity. Lectins such as PNA prefer TF but can bind related structures; antibody and lectin results are not interchangeable.
- Sialidase exposure. Bacterial contamination or delayed processing can remove sialic acid in the tube and create TF that was not present in the patient.
- Natural antibodies. Circulating anti-T antibodies can bind TF-bearing molecules and mask or alter results in solution assays.
- No reference standard. Without an agreed calibrator or reference range, "high" depends on the method used.
Causes compared
Causes of high TF antigen at a glance
| Cause | Mechanism | Where it is seen | Why it matters |
|---|---|---|---|
| Cancer | Stalled O-glycan elongation, sialylation shifts, mucin overexpression | Many carcinomas, some leukemias | Linked to progression and prognosis; research diagnostic target |
| Infection | Microbial neuraminidase removes sialic acid | Red cells, platelets, endothelium | T-activation, hemolysis, pneumococcal HUS |
| Inflammation | Altered mucin glycosylation | Ulcerative colitis, some precancerous lesions | Major source of false positives |
| Development | Oncofetal expression | Fetal tissue; low background in some adult tissue | Background signal to account for |
| Measurement | Reagent cross-reactivity, sample desialylation, antibodies | Any assay | Apparent high results without disease |
Interpreting results
What does a high TF antigen result mean?
For patients and families: a high TF result on its own does not mean cancer. There is currently no validated clinical blood test or reference range for TF antigen, and TF can rise with infection, inflammation and other conditions. If you are concerned about cancer, talk with your clinician about established, guideline-recommended tests.
For researchers, a TF result is most informative when the method is defined (lectin or antibody, the glycoform measured), when samples are handled to prevent desialylation, when sialyl-TF and Tn are considered alongside TF, and when comparison groups include people with inflammatory and benign disease, not only healthy volunteers.
OncoFirm™ research
Turning TF biology into responsible diagnostics
Because TF can rise for many reasons, OncoFirm™’s approach starts with the causes on this page. A useful TF measurement must separate tumor-related glycosylation from infection, inflammation and handling artifacts, and should be read together with other markers.
Defined measurement
Capture reagents chosen and characterized for TF versus sialyl-TF and Tn, with sample-handling rules that prevent artificial desialylation.
Specificity by design
Validation plans that include infection, inflammatory bowel disease and other benign conditions. Clinical collaborations
Quantitative fluorescence
A fluorescent strip and handheld reader intended to report numbers that can be compared over time. Platform
Panels, not single markers
Research on TF alongside CEA, PSA and AFP in pipeline concepts such as OncoFirm™-R, OncoFirm™-B and OncoFirm™-L.
OncoFirm™ TF-antigen concepts are in development, have not been cleared or approved by the FDA or any other regulatory authority, and are for research use only. Blood measurement of TF antigen is at an early research stage.
FAQ
Frequently asked questions
What is the Thomsen–Friedenreich (TF) antigen?
The TF antigen, also called the T antigen or CD176, is a two-sugar structure (galactose-β1,3-N-acetylgalactosamine) attached to proteins. On most healthy cells it is hidden by sialic acid or built into longer sugar chains; it becomes exposed in many cancers and in some non-cancerous conditions.
What causes the TF antigen to become exposed?
The main causes are changes in glycosylation inside cancer cells, removal of sialic acid by microbial neuraminidase enzymes during certain infections, inflammation such as ulcerative colitis, and normal fetal development. Laboratory factors can also produce apparent TF signals.
Does high TF antigen mean I have cancer?
No. TF exposure is associated with many carcinomas, but it also occurs in infection, inflammation and other conditions, and there is no validated clinical blood test or reference range for TF antigen. Any concern about cancer should be discussed with a clinician, who will use established tests.
What is T-activation?
T-activation happens when bacterial or viral neuraminidase, for example from Streptococcus pneumoniae or Clostridium perfringens, strips sialic acid from red cells and exposes TF. Because most people over about six months of age carry natural anti-T IgM, this can contribute to hemolysis, as in pneumococcal hemolytic uremic syndrome.
Is TF the same as Tn or sialyl-Tn?
No. Tn is the single GalNAc sugar one step earlier in the pathway, and sialyl-Tn is Tn capped with sialic acid. Loss of the chaperone Cosmc blocks TF formation and exposes Tn instead. All three are tumor-associated carbohydrate antigens, but they arise by different mechanisms.
Is there an FDA-cleared blood test for TF antigen?
No TF-antigen-based blood test is currently cleared or approved by the U.S. FDA for cancer detection. OncoFirm™ is researching TF antigen measurement; its assays are in development and for research use only.
Keep reading
Related guides
Sources
References
- Springer GF. T and Tn, general carcinoma autoantigens. Science. 1984;224(4654):1198–1206. doi.org/10.1126/science.6729450
- Yu LG. The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression. Glycoconjugate Journal. 2007;24:411–420. doi.org/10.1007/s10719-007-9034-3
- Burchell JM, et al. O-linked mucin-type glycosylation in breast cancer. Biochemical Society Transactions. 2018;46(4):779–788. portlandpress.com/biochemsoctrans/article/46/4/779/67123/O-linked-mucin-type-glycosylation-in-breast-cancer
- Ju T, Cummings RD. Protein glycosylation: chaperone mutation in Tn syndrome. Nature. 2005;437:1252. www.nature.com/articles/4371252a
- Ju T, Lanneau GS, Gautam T, et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Research. 2008;68(6):1636–1646. aacrjournals.org/cancerres/article/68/6/1636/543159/Human-Tumor-Antigens-Tn-and-Sialyl-Tn-Arise-from
- Campbell BJ, Finnie IA, Hounsell EF, Rhodes JM. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. J Clin Invest. 1995;95(2):571–576. pubmed.ncbi.nlm.nih.gov/7860740/
- Baldus SE, Zirbes TK, Hanisch FG, et al. Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma. Cancer. 2000;88(7):1536–1543. acsjournals.onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(20000401)88:7%3C1536::AID-CNCR6%3E3.0.CO;2-W
- Oliver JW, Akins RS, Bibens MK, Dunn DM. Pneumococcal induced T-activation with resultant thrombotic microangiopathy. Clin Med Insights Pathol. 2010;3:13–17. pmc.ncbi.nlm.nih.gov/articles/PMC2999997/
- Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nature Medicine. 2008;14:648–655. www.nature.com/articles/nm1760
- Yu LG, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007;282(1):773–781. doi.org/10.1074/jbc.M606862200
About this article. Written by the OncoFirm™ Scientific Team from peer-reviewed publications, all linked above. OncoFirm™ was not involved in the studies discussed. This article is for education and is not medical advice; it cannot be used to interpret an individual test result. OncoFirm™ assays are in development, have not been cleared or approved by the FDA and are not available for sale.
Collaborate on TF and glycan biomarker research
Glycobiology groups, pathologists, transfusion specialists and clinical partners working on TF, Tn or sialyl-TF can explore joint studies with OncoFirm™. Collaboration inquiry